Pfizer reported Q3 2026 financial results

Item 2.02 Results of Operations and Financial Condition

On November 3, 2026, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for the third quarter of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.¹

The information furnished pursuant to this "Item 2.02 - Results of Operations and Financial Condition", including Exhibit 99, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Exhibit Description

Exhibit 99

Press Release of Pfizer Inc. dated November 3, 2026 , reporting Pfizer's financial results for the third quarter of 2026.

104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

EXHIBIT INDEX

Exhibit No. Description

99

Press Release of Pfizer Inc. dated November 3, 2026, reporting Pfizer's financial results for the third quarter of 2026.

104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

By: /s/ Margaret M. Madden

Margaret M. Madden

Senior Vice President and Corporate Secretary

Chief Governance Counsel

Dated: November 3, 2026

Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance²

■ Focused Execution Drove 32% Operational Revenue Growth of Launched and Acquired Products² (1)

■ Advancing Robust Late-Stage Pipeline with Multiple Key Catalysts Ahead

■ Raises 2026 Guidance (2) on Strong Year-to-Date Performance³

■ Appoints Cecile Guegan Chief Financial Officer, Executive Vice President

NEW YORK, Tuesday, November 3, 2026 — Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance (2) for both Revenues and Adjusted (3) diluted EPS.

EXECUTIVE COMMENTARY

Dr. Albert Bourla, Chairman and CEO of Pfizer:

"Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected cat